Nanobiotix' Partner PharmaEngine Has Launched a New NBTXR3 Clinical Trial in Head and Neck Cancers in Asia
- Written by ACN Newswire
<p><p><img src="http://www.acnnewswire.com/images/company/nanobiotix.jpg" border="0" /></p>Paris, France and Cambridge, Massachusetts, USA, Nov 7, 2016 - (ACN Newswire) - NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of...